Xiangcai Securities: Performance divergence observed in the chemical formulations and medical services sectors; focus on pharmaceutical companies with high growth potential, improving outlooks, and sustained innovation capabilities.

The phase of high industry-wide growth has passed. Under the dual pressures of rising demand driven by an aging population and mounting strain on medical insurance funds, the industry's primary challenge has shifted from 'insufficient effective supply' to a new phase centered on 'medical insurance cost containment.'

Zhitong FinanceMay 21 03:53 ET

We Think That There Are Some Issues For Betta Pharmaceuticals (SZSE:300558) Beyond Its Promising Earnings

Simply Wall StMay 5 18:43 ET

Xcovery Partners With EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.

PR NewswireApr 27 07:55 ET

Medicine Chronicles ⑦: With over 70 billion yuan in revenue, how did China create a domestic "blockbuster drug"?

① The development of China's innovative pharmaceuticals sector has indeed been rapid. In addition to antibody drugs, cutting-edge fields such as cell and gene therapy, as well as small nucleic acid drugs, are also accelerating. Based on the number of early-stage research projects and clinical pipelines, China’s innovative pharmaceutical industry is continuously catching up with mature markets in Europe and the United States, with certain sub-sectors already able to rival them; ② The core logic by which the current market evaluates innovative drugs essentially remains expanding growth potential through overseas expansion.

cls.cnApr 25 07:38 ET

Beta Pharma: First Quarter Report for 2026

SZSIApr 22 12:00 ET · Announcements

Beta Pharma: 2025 Annual Report

SZSIApr 22 12:00 ET · Announcements